(VIANEWS) – New York Community Bancorp (NYCB), Genmab (GMAB), Republic First Bancorp (FRBK) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. New York Community Bancorp (NYCB)
95.3% sales growth and 8.19% return on equity
New York Community Bancorp, Inc. operates as a bank holding company for New York Community Bank that provides banking products and services in Metro New York, New Jersey, Ohio, Florida, and Arizona. The company offers various deposit products, including interest-bearing checking and money market, savings, non-interest-bearing, and individual retirement accounts, as well as certificates of deposit. It also provides multi-family loans; commercial real estate loans; specialty finance loans and leases, and other commercial and industrial loans; acquisition, development, and construction loans; one-to-four family loans; and consumer loans. In addition, the company offers annuities, life and long-term care insurance products, and mutual funds; cash management products; and online, mobile, and phone banking services. It primarily serves individuals, small and mid-size businesses, and professional associations through a network of 238 community bank branches and 348 ATM locations. The company was formerly known as Queens County Bancorp, Inc. and changed its name to New York Community Bancorp, Inc. in November 2000. New York Community Bancorp, Inc. was founded in 1859 and is headquartered in Westbury, New York.
Earnings Per Share
As for profitability, New York Community Bancorp has a trailing twelve months EPS of $1.26.
PE Ratio
New York Community Bancorp has a trailing twelve months price to earnings ratio of 6.89. Meaning, the purchaser of the share is investing $6.89 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.19%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 28.1% and a negative 5.7%, respectively.
Previous days news about New York Community Bancorp(NYCB)
- According to Zacks on Wednesday, 26 April, "Another stock from the same industry, New York Community Bancorp (NYCB Quick QuoteNYCB – Free Report) , has yet to report results for the quarter ended March 2023. "
2. Genmab (GMAB)
29.1% sales growth and 22.25% return on equity
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $1.24.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 32.96. Meaning, the purchaser of the share is investing $32.96 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.25%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 481.8% and 395.1%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 99.6%, now sitting on 14.6B for the twelve trailing months.
Moving Average
Genmab’s worth is higher than its 50-day moving average of $37.73 and higher than its 200-day moving average of $38.21.
3. Republic First Bancorp (FRBK)
14% sales growth and 6.96% return on equity
Republic First Bancorp, Inc. operates as the holding company for Republic First Bank that provides a range of credit and depository banking products and services to individuals and businesses. It accepts consumer and commercial deposit, checking, interest-bearing demand, money market, savings, sweep, and individual retirement accounts, as well as certificates of deposit. The company also offers secured and unsecured commercial, real estate, construction and land development, automobile, and home improvement loans; mortgages, home equity and overdraft lines of credit, and other products; and lockbox services. As of April 5, 2022, it operated 34 offices located in Atlantic, Burlington, Camden, and Gloucester counties in New Jersey; Bucks, Delaware, Montgomery, and Philadelphia counties in Pennsylvania; and New York County in New York. Republic First Bancorp, Inc. was founded in 1987 and is based in Philadelphia, Pennsylvania.
Earnings Per Share
As for profitability, Republic First Bancorp has a trailing twelve months EPS of $0.23.
PE Ratio
Republic First Bancorp has a trailing twelve months price to earnings ratio of 5.48. Meaning, the purchaser of the share is investing $5.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.96%.
Sales Growth
Republic First Bancorp’s sales growth is 4.6% for the present quarter and 14% for the next.
Volume
Today’s last reported volume for Republic First Bancorp is 517312 which is 28.45% below its average volume of 723014.
Moving Average
Republic First Bancorp’s value is way below its 50-day moving average of $1.62 and way under its 200-day moving average of $2.57.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5%, now sitting on 164.07M for the twelve trailing months.
4. EMCOR Group (EME)
10.9% sales growth and 19.21% return on equity
EMCOR Group, Inc. provides electrical and mechanical construction, and facilities services primarily in the United States and the United Kingdom. It offers design, integration, installation, starts-up, operation, and maintenance services related to electrical power transmission, distribution, and generation systems; energy solutions; premises electrical and lighting systems; process instrumentation in the refining, chemical processing, and food processing industries; low-voltage systems, such as fire alarm, security, and process control systems; voice and data communications systems; roadway and transit lighting, signaling, and fiber optic lines; heating, ventilation, air conditioning, refrigeration, and geothermal solutions; clean-room process ventilation systems; fire protection and suppression systems; plumbing, process, and high-purity piping systems; controls and filtration systems; water and wastewater treatment systems; central plant heating and cooling systems; crane and rigging services; millwright services; and steel fabrication, erection, and welding services. The company also provides building services that cover commercial and government site-based operations and maintenance; facility management, maintenance, and services; outage services to utilities and industrial plants; military base operations support services; mobile mechanical maintenance and services; services for indoor air quality; floor care and janitorial services; landscaping, lot sweeping, and snow removal services; vendor management and call center services; installation and support for building systems; program development, management, and maintenance for energy systems; technical consulting and diagnostic services; infrastructure and building projects; small modification and retrofit projects; and other building services. It offers industrial services to oil, gas, and petrochemical industries. EMCOR Group, Inc. was incorporated in 1987 and is headquartered in Norwalk, Connecticut.
Earnings Per Share
As for profitability, EMCOR Group has a trailing twelve months EPS of $8.16.
PE Ratio
EMCOR Group has a trailing twelve months price to earnings ratio of 19.11. Meaning, the purchaser of the share is investing $19.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.21%.
Yearly Top and Bottom Value
EMCOR Group’s stock is valued at $155.91 at 06:22 EST, under its 52-week high of $169.89 and way higher than its 52-week low of $95.64.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 13, 2023, the estimated forward annual dividend rate is 0.72 and the estimated forward annual dividend yield is 0.47%.
5. Haemonetics Corporation (HAE)
8.9% sales growth and 12.71% return on equity
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Earnings Per Share
As for profitability, Haemonetics Corporation has a trailing twelve months EPS of $1.88.
PE Ratio
Haemonetics Corporation has a trailing twelve months price to earnings ratio of 45.1. Meaning, the purchaser of the share is investing $45.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.71%.
Volume
Today’s last reported volume for Haemonetics Corporation is 178365 which is 53.37% below its average volume of 382585.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Haemonetics Corporation’s EBITDA is 68.17.
6. Cooper Companies (COO)
6.4% sales growth and 5.26% return on equity
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Earnings Per Share
As for profitability, Cooper Companies has a trailing twelve months EPS of $7.56.
PE Ratio
Cooper Companies has a trailing twelve months price to earnings ratio of 49.48. Meaning, the purchaser of the share is investing $49.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.26%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jan 19, 2023, the estimated forward annual dividend rate is 0.06 and the estimated forward annual dividend yield is 0.02%.
Sales Growth
Cooper Companies’s sales growth is 4% for the ongoing quarter and 6.4% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Cooper Companies’s EBITDA is 6.21.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 7.1% and positive 4.1% for the next.
Previous days news about Cooper Companies(COO)
- According to Zacks on Wednesday, 26 April, "Industry participants like West Pharmaceutical Services (WST Quick QuoteWST – Free Report) , The Cooper Companies (COO Quick QuoteCOO – Free Report) and Henry Schein (HSIC Quick QuoteHSIC – Free Report) have shown resiliency despite uncertain conditions and are likely to gain from the existing opportunities."
7. Aon plc (AON)
6.2% sales growth and 725.93% return on equity
Aon plc, a professional services firm, provides advice and solutions to clients focused on risk, retirement, and health worldwide. It offers commercial risk solutions, including retail brokerage, specialty solutions, global risk consulting and captives management, and affinity programs; and health solutions, such as health and benefits brokerages, and health care exchanges. The company also provides treaty and facultative reinsurance, as well as insurance-linked securities, capital raising, strategic advice, restructuring, and mergers and acquisitions services; and corporate finance advisory services. In addition, it offers strategic design consulting services on their retirement programs, actuarial services, and risk management services; advice services on developing and maintaining investment programs across a range of plan types, including defined benefit plans, defined contribution plans, endowments, and foundations for public and private companies, and other institutions; and advice and solutions that help clients in risk, health, and wealth through commercial risk, reinsurance, health, and wealth solutions. Aon plc was founded in 1919 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, Aon plc has a trailing twelve months EPS of $12.21.
PE Ratio
Aon plc has a trailing twelve months price to earnings ratio of 26.79. Meaning, the purchaser of the share is investing $26.79 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 725.93%.
Moving Average
Aon plc’s value is above its 50-day moving average of $310.58 and way higher than its 200-day moving average of $297.05.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.6%, now sitting on 12.48B for the twelve trailing months.
Volume
Today’s last reported volume for Aon plc is 320582 which is 63.6% below its average volume of 880900.
8. Franklin Covey Company (FC)
5.1% sales growth and 21.57% return on equity
Franklin Covey Co. provides training and consulting services in the areas of execution, sales performance, productivity, customer loyalty, and educational improvement for organizations and individuals worldwide. The company operates through three segments: Direct Offices, International Licensees, and Education Practice. It also provides a suite of individual-effectiveness and leadership-development training and products. The company was incorporated in 1983 and is headquartered in Salt Lake City, Utah.
Earnings Per Share
As for profitability, Franklin Covey Company has a trailing twelve months EPS of $1.35.
PE Ratio
Franklin Covey Company has a trailing twelve months price to earnings ratio of 29.16. Meaning, the purchaser of the share is investing $29.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.57%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 66.7% and positive 15.4% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Franklin Covey Company’s EBITDA is 1.8.
Yearly Top and Bottom Value
Franklin Covey Company’s stock is valued at $39.37 at 06:22 EST, way below its 52-week high of $54.70 and way higher than its 52-week low of $34.00.
